Market Feasibility Study of Rabeprazole Sodium

Abstract

A peptic ulcer is damage to the lining of the stomach, duodenum, or esophagus due to corrosion caused by gastric acid or digestive juices secreted by stomach cells. Among all classes of drugs, proton pump inhibitors are the most effective for the management of peptic ulcer diseases. Rabeprazole sodium is one of the prominent proton pump inhibitors. It is commonly used in the world for the treatment of peptic ulcer. It functions by inhibiting the enzyme W /K+ ATPase which is responsible for the secretion of gastric acid. The purpose of this study is to analyze the market feasibility study of Rabeprazole sodium. Many books, journals and different articles were used to know efficacy and safety profile of drugs. Rabeprazole sodium blocks acid production in the stomach. It is prescribed for the short-term (4 to 8 weeks) treatment of sores and inflammation in the upper digestive canal (esophagus). It is more effective in the treatment of duodenal ulcer, H. pylori, gastric ulcer, erosive esophagitis, GERD, and pathological hypersecretory conditions, including Zollinger-Ellison syndrome. By the study of market, feasibility among all PPls Rabeprazole market value is 26,568,572 taka. Rabeprazole market growth is 2.29%, which is comparatively less among other PPls. To increase overall market growth I can introduce Rabeprazole sodium, which is a delayed-release tablet. Because of its D-R property I hope that with in one year it will become a superior drug for the ,treatment of peptic ulcer.